Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 14, 2023

Prognostic Value of Metabolic Tumor Volume in Patients With Advanced-Stage Follicular Lymphoma Receiving Lenalidomide and Rituximab or Rituximab-Based Chemotherapy

Annals of Oncology

 

Additional Info

Annals of Oncology
Metabolic tumor volume predicts outcome in advanced stage follicular lymphoma patients from the Relevance trial
Ann. Oncol 2023 Oct 26;[EPub Ahead of Print], AS Cottereau, L Rebaud, J Trotman, P Feugier, LJ Nastoupil, E Bachy, IW Flinn, C Haioun, L Ysebaert, NL Bartlett, H Tilly, O Casasnovas, R Ricci, C Portugues, I Buvat, M Meignan, F Morschhauser

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading